Documents & Downloads

TGN, Cys modified

Drug Derivative

TGN, Cys modified is a cysteine-conjugated derivative of the 12-amino acid ligand TGN, designed to facilitate the delivery of therapeutic agents across the blood-brain barrier. This modification enhances the stability and bioavailability of TGN, making it suitable for use as a drug delivery vehicle in Alzheimer’s disease research. It provides a promising approach for targeting central nervous system disorders, allowing for enhanced therapeutic efficacy and potential treatment strategies.

Out of Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer	Adooq Bioscience
Actions	Ligand / Binder
CAS Number	1418155-47-1
Applications	Drug Derivative
Formula	C₆₀H₉₀N₂₀O₁₈S
Molecular Weight	1411.54

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.